HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.

Abstract
Hypoxia and necrosis are fundamental features of glioblastoma (GBM) and their emergence is critical for the rapid biological progression of this fatal tumor; yet, underlying mechanisms are poorly understood. We have suggested that vaso-occlusion following intravascular thrombosis could initiate or propagate hypoxia and necrosis in GBM. Tissue factor (TF), the main cellular initiator of coagulation, is overexpressed in GBMs and likely favors a thrombotic microenvironment. Epidermal growth factor receptor (EGFR) amplification and PTEN loss are two common genetic alterations seen in GBM but not in lower-grade astrocytomas that could be responsible for TF up-regulation. The most frequent EGFR mutation in GBM involves deletion of exons 2 to 7, resulting in the expression of a constitutively active receptor, EGFRvIII. Here, we show that overexpression of EGFR or EGFRvIII in human glioma cells causes increased basal TF expression and that stimulation of EGFR by its ligand, EGF, leads to a marked dose-dependent up-regulation of TF. In all cases, increased TF expression led to accelerated plasma coagulation in vitro. EGFR-mediated TF expression depended most strongly on activator protein-1 (AP-1) transcriptional activity and was associated with c-Jun NH(2)-terminal kinase (JNK) and JunD activation. Restoration of PTEN expression in PTEN-deficient GBM cells diminished EGFR-induced TF expression by inhibiting JunD/AP-1 transcriptional activity. PTEN mediated this effect by antagonizing phosphatidylinositol 3-kinase activity, which in turn attenuated both Akt and JNK activities. These mechanisms are likely at work in vivo, as EGFR expression was highly correlated with TF expression in human high-grade astrocytoma specimens.
AuthorsYuan Rong, Vladimir E Belozerov, Carol Tucker-Burden, Gang Chen, Donald L Durden, Jeffrey J Olson, Erwin G Van Meir, Nigel Mackman, Daniel J Brat
JournalCancer research (Cancer Res) Vol. 69 Issue 6 Pg. 2540-9 (Mar 15 2009) ISSN: 1538-7445 [Electronic] United States
PMID19276385 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Phosphoinositide-3 Kinase Inhibitors
  • Proto-Oncogene Proteins c-jun
  • Transcription Factor AP-1
  • epidermal growth factor receptor VIII
  • Epidermal Growth Factor
  • Thromboplastin
  • ErbB Receptors
  • Oncogene Protein v-akt
  • JNK Mitogen-Activated Protein Kinases
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • PTEN Phosphohydrolase
  • PTEN protein, human
Topics
  • Brain Neoplasms (enzymology, genetics, metabolism)
  • Cell Line, Tumor
  • Epidermal Growth Factor (pharmacology)
  • ErbB Receptors (biosynthesis, genetics, metabolism)
  • Glioblastoma (enzymology, genetics, metabolism)
  • Humans
  • JNK Mitogen-Activated Protein Kinases (metabolism)
  • MAP Kinase Signaling System
  • Mitogen-Activated Protein Kinase 1 (metabolism)
  • Mitogen-Activated Protein Kinase 3 (metabolism)
  • Oncogene Protein v-akt (metabolism)
  • PTEN Phosphohydrolase (genetics, metabolism)
  • Phosphatidylinositol 3-Kinases (metabolism)
  • Phosphoinositide-3 Kinase Inhibitors
  • Promoter Regions, Genetic
  • Proto-Oncogene Proteins c-jun (biosynthesis, genetics)
  • Signal Transduction
  • Thromboplastin (biosynthesis, genetics)
  • Transcription Factor AP-1 (biosynthesis, genetics)
  • Transcription, Genetic
  • Up-Regulation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: